Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea (PolySAS)
Primary Purpose
Obstructive Sleep Apnea
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
one month polyphenols supplementation (600mg)
placebo (microcrystalline cellulose)
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea focused on measuring sleep apnea, polyphenols, endothelial function
Eligibility Criteria
Inclusion Criteria:•
- apnea hypopnea index > 30
- accepting polyphenols supplementation
- Signed informed consent
Exclusion Criteria:
- Epworth sleepiness scale > 16/24
- Severe cardiac and/or respiratory disease
- BMI>35 kg/m2
- Anemia
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
polyphenols
Placebo
Arm Description
600 mg polyphenols (grape extract)
microcrystalline cellulose
Outcomes
Primary Outcome Measures
endothelial function measured by the index of hyperemic reactivity
Secondary Outcome Measures
Full Information
NCT ID
NCT01977924
First Posted
October 31, 2013
Last Updated
November 12, 2013
Sponsor
University Hospital, Angers
1. Study Identification
Unique Protocol Identification Number
NCT01977924
Brief Title
Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea
Acronym
PolySAS
Official Title
Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Unknown status
Study Start Date
November 2013 (undefined)
Primary Completion Date
May 2015 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Angers
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Severe obstructive sleep apnea (OSA) is associated with increased cardiovascular morbidity and mortality. Endothelial dysfunction, an early marker of vascular disease has been demonstrated in OSA. Regular treatment of OSA by continuous positive airway pressure (CPAP) improves endothelial function and is associated with a reduction in cardiovascular risk. Approximately 40% of patients with OSA are intolerant or insufficiently adherent to CPAP. Alternative treatments or adjuvants to the CPAP are needed.
The polyphenols have demonstrated their effectiveness in improving endothelial function in patients with CV disease. No randomized controlled studies have evaluated the impact of PPR on the endothelial dysfunction associated with OSAHS.
Detailed Description
The endpoint is the change to one month of polyphenols treatment of the endothelial function measured by the index of hyperemic reactivity.
The secondary endpoints are changes at one month of supplementation with polyphenols of ambulatory blood pressure measurement in 24 hours (MAPA), micro-circulatory responsiveness, the speed of the pulse wave and biological measurements (lipid profile, blood glucose, fasting insulin, leptin, adiponectin, hs-CRP, 8-isoprostane levels and cellular origin of microparticles).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea
Keywords
sleep apnea, polyphenols, endothelial function
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
polyphenols
Arm Type
Experimental
Arm Description
600 mg polyphenols (grape extract)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
microcrystalline cellulose
Intervention Type
Dietary Supplement
Intervention Name(s)
one month polyphenols supplementation (600mg)
Intervention Type
Dietary Supplement
Intervention Name(s)
placebo (microcrystalline cellulose)
Primary Outcome Measure Information:
Title
endothelial function measured by the index of hyperemic reactivity
Time Frame
one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:•
apnea hypopnea index > 30
accepting polyphenols supplementation
Signed informed consent
Exclusion Criteria:
Epworth sleepiness scale > 16/24
Severe cardiac and/or respiratory disease
BMI>35 kg/m2
Anemia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
wojciech trzepizur, MD
Phone
+33(0) 214353695
Email
wotrzepizur@chu-angers.fr
12. IPD Sharing Statement
Citations:
PubMed Identifier
29659956
Citation
Trzepizur W, Bironneau V, Recoquillon S, Priou P, Meslier N, Hamel JF, Henni S, Darsonval A, Messaoudi K, Martinez MC, Andriantsitohaina R, Gagnadoux F. Polyphenols Have No Impact on Endothelial Function in Patients with Obstructive Sleep Apnea: A Randomized Controlled Trial. J Nutr. 2018 Apr 1;148(4):581-586. doi: 10.1093/jn/nxy005.
Results Reference
derived
Learn more about this trial
Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea
We'll reach out to this number within 24 hrs